Investigation of Fibroblast Growth Factor Peptide Antagonist on Mouse Model Breast Tumor through ERK/MAPK and PI3K/AKT Signaling Pathways

Document Type : Research Articles

Authors

1 Department of Biochemistry and Biophysics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

2 Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

3 Department of Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Science, Tehran, Iran.

5 Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Tehran, Iran.

Abstract

Background: In the majority of cancers, metastasis of tumor cells is the main cause of treatment failure. This study intended to investigate the effectiveness of basic fibroblast growth factor (bFGF) peptide designed to inhibit tumor growth in 4T1 metastatic breast cancer through the PI3K/AKT and ERK/MAPK signal transduction pathways. Methods: The tumor was induced through 4T1 tumor graft in BALB/c mice. The designed peptide was injected intraperitoneal at three selected doses after two weeks for 14 days. The PBS and doxorubicin were used as the negative and positive control groups, respectively. Tumor size was measured and after the treatment period, the mice underwent a surgery and tumors were used for the western blot examinations. Results: the peptide injection was effective in reducing or inhibiting tumor growth in mice model and in vitro. The western blot analysis results showed that the p-AKT and p-ERK levels in peptide treated tumors were reduced (p<0.05). Conclusion: The peptide injection was effective in mice model. Findings showed that in the two signal transduction pathways, the p-AKT and p-ERK levels were significantly different from the negative control group.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 25, Issue 2
February 2024
Pages 473-483

Files

History

  • Receive Date: 29 July 2023
  • Revise Date: 16 December 2023
  • Accept Date: 11 February 2024

Share

How to cite

Statistics